

University of Groningen

Exploring new ways of measuring the economic value of vaccination with an application to the prevention of rotaviral disease

Standaert, Baudouin Arnould Claire Ghislain Marie

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Standaert, B. A. C. G. M. (2015). *Exploring new ways of measuring the economic value of vaccination with an application to the prevention of rotaviral disease*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

LIST OF PUBLICATIONS

1. Comparing Cost-Effectiveness Results for a Vaccine Across Different Countries Worldwide: What Can We Learn? Baudouin Standaert, Olivier Ethgen, Rachel Emerson, Maarten Postma, Josephine Mauskopf *Advances in Therapy*. 10/2014, 1095-108
2. Public health impact of accelerated immunization against rotavirus infection among children aged less than 6 months in the United States. Derek Weycker, Mark Andrew Atwood, Baudouin Standaert, Girishanthi Krishnarajah *Human vaccines & immunotherapeutics*. 04/2014; 10(7).
3. Budget constraint and vaccine dosing: a mathematical modelling exercise. Baudouin A Standaert, Desmond Curran, Maarten J Postma. *Cost Effectiveness and Resource Allocation* 01/2014; 12(1):3. doi: 10.1186/1478-7547-12-3
4. Reassessing the value of vaccines. Till Bärnighausen, Seth Berkley, Zulfiqar A Bhutta, David M Bishai, Maureen M Black, David E Bloom, Dagna Constenla, Julia Driessen, John Edmunds, David Evans, [.....], Bruce Y Lee, Sharmila Mhatre, Anne Mills, Anders Nordström, Sachiko Ozawa, Lisa Prosser, Karlee Silver, Christine Stabell Benn, Baudouin Standaert, Damian Walker. *The Lancet Global Health*. 01/2014; 2(5):e251–e252.
5. Economics of vaccines revisited. Maarten J Postma, Baudouin A Standaert *Human vaccines & immunotherapeutics*. 01/2013; 9(5).
6. Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data. Baudouin Standaert, Jorge A Gomez, Marc Raes, Serge Debrus, F Raúl Velázquez, Maarten J Postma. *PLoS ONE* 01/2013; 8(1):e53864.
7. Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany? Stefanie Knoll, Christoph Mair, Ursula Benter, Katja Vouk, Baudouin Standaert *Health economics review*. 01/2013; 3(1):27.
8. Estimating and comparing the clinical and economic impact of pediatric rotavirus vaccination in Turkey using a simple versus an advanced model. Mustafa Bakir, Baudouin Standaert, Ozden Turel, Ece Bilge, Maarten Postma. *Vaccine* 12/2012;
9. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Mark P Connolly, Oleksandr Topachevskyi, Baudouin Standaert, Omayra Ortega, Maarten Postma. *PharmacoEconomics* 08/2012; 30(8):681-95.
10. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Josephine Mauskopf, Sandra Talbird, Baudouin Standaert *Expert Review of Pharmacoeconomics & Outcomes Research* 06/2012; 12(3):357-71.
11. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Nadia Demarteau, Thomas Breuer, Baudouin Standaert. *PharmacoEconomics* 04/2012; 30(4):337-53.
12. Population- versus cohort-based modelling approaches. Olivier Ethgen, Baudouin Standaert *PharmacoEconomics* 03/2012; 30(3):171-81.

13. Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States. Girishanthu Krishnarajah, Elizabeth J Davis, Ying Fan, Baudouin A Standaert, Ami R Buikema *Vaccine* 12/2011; 30(24):3717-22.
14. Public health impact of human papillomavirus vaccination on prevention of cervical cancer in France. Abdelkader El Hasnaoui, Nadia Demarteau, Denis Granados, Baudouin Standaert, Bruno Detournay *International Journal of Public Health* 06/2011; 57(1):149-58.
15. Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. Mark H Rozenbaum, Marie-Josée J Mangen, Carlo Giaquinto, Jan C Wilschut, Eelko Hak, Maarten J Postma, CoRoVa-Group as following, Najy Alsayed, Maarten Boomsma, Rachel Emerson, [.....], Nathalie LARGERON, Marie-Josée J. Mangen, Jelle Mathijnsens, John J Roord, Hans C Rumke, Beaudouin Standaert, Sibilica Quilici, Timo Vesikari, Max Zeller, Bernhard A.M. van der Zeijst *BMC Public Health* 06/2011; 11:462.
16. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Marc Raes, Danielle Strens, Anne Vergison, Marc Verghote, Baudouin Standaert *The Pediatric Infectious Disease Journal* 03/2011; 30(7):e120-5.
17. Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. Maarten J Postma, Mark Jit, Mark H Rozenbaum, Baudouin Standaert, Hong-Anh Tu, Raymond C W Hutubessy. *BMC Medicine* 01/2011; 9:84.
18. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Nadia Demarteau, Bruno Detournay, Bertrand Tehard, Abdelkader El Hasnaoui, Baudouin Standaert *International Journal of Public Health* 11/2010; 56(2):153-62.
19. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Baudouin Standaert, Nadia Demarteau, Sandra Talbird, Josephine Mauskopf. *Vaccine* 11/2010; 28 Suppl 6:G30-8.
20. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. Nadia Demarteau, Baudouin Standaert. *Journal of Medical Economics* 01/2010; 13(2):324-38.
21. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Lisandro Colantonio, Jorge A Gómez, Nadia Demarteau, Baudouin Standaert, Andrés Pichón-Rivière, Federico Augustovski *Vaccine* 08/2009; 27(40):5519-29.
22. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. A Martin, A Batty, J A Roberts, B Standaert. *Vaccine* 06/2009; 27(33):4520-8.
23. Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. Lucas Goossens, Baudouin Standaert, Nico Hartwig, Anke M Hövels, Maiwenn J Al *Vaccine* 05/2009; 27(19):2531-2.

24. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Donna Debicki, Nicole Ferko, Nadia Demarteau, Steve Gallivan, Chris Bauch, Andrea Anonychuk, Lorenzo Mantovani, Stefano Capri, Cheng-Yang Chou, Baudouin Standaert, Lieven Annemans *Vaccine* 10/2008; 26 Suppl 5:F16-28.
25. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Eugenio Suárez, Jennifer S Smith, F Xavier Bosch, Pekka Nieminen, Chien-Jen Chen, Saku Torvinen, Nadia Demarteau, Baudouin Standaert *Vaccine* 10/2008; 26 Suppl 5:F29-45.
26. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Lucas M A Goossens, Baudouin Standaert, Nico Hartwig, Anke M Hövels, Maiwenn J Al *Vaccine* 03/2008; 26(8):1118-27.
27. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Baudouin Standaert, Nathalie Perez, Bertrand Tehard, Xavier Colin, Bruno Detournay *Applied Health Economics and Health Policy* 02/2008; 6(4):199-216.
28. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. Alan Martin, Suzanne Cottrell, Baudouin Standaert *Journal of Medical Economics*. 2008,11: 471-484.
29. Resource use and cost analysis of managing abnormal Pap smears: a retrospective study in five countries. B Rash, P Martin-Hirsch, A Schneider, M Sideri, J Tan, A Torné, B Standaert *European journal of gynaecological oncology* 01/2008; 29(3):225-32.
30. The Financial Burden of Rotavirus Disease in Four Countries of the European Union Baudouin Standaert, Olof Harlin, Ulrich Desselberger *The Pediatric Infectious Disease Journal* 12/2007; 27(1):S20-S27.
31. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales. P Martin-Hirsch, B Rash, A Martin, B Standaert *BJOG An International Journal of Obstetrics & Gynaecology* 05/2007; 114(4):408-15.
32. Évaluation de l'impact en santé publique de la vaccination contre le HPV dans la prévention du cancer du col en France A. El Hasnaoui, B. Detournay, N. Demarteau, D. Granados, B. Standaert *Revue D Epidemiologie Et De Sante Publique - REV EPIDEMIOLOGIE SANTE PUBL.* 01/2007; 55(1).
33. Estimating resource use and cost of prophylactic management of neutropenia with filgrastim. L Annemans, N Van Overbeke, B Standaert, S Van Belle *Journal of Nursing Management* 06/2005; 13(3):265-74.
34. Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data. Standaert B, Goldstone J, Lu ZJ, Erder MH, Yin JL. *Pharmacoeconomics*. 2002;20(10):665-74.
35. [Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France]. L Perrier, C Sebban, I Philip, B Standaert, M Morelle, J F Latour, P Biron, T Philip *Revue d Épidémiologie et de Santé Publique* 10/2002; 50(4):393-403.

36. Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. D Curran, N Aaronson, B Standaert, G Molenberghs, P Therasse, A Ramirez, M Koopmanschap, H Erder, M Piccart *European Journal of Cancer* 06/2000; 36(7):834-44.
37. Filgrastim in the Treatment of Infected Diabetic Foot Ulcers: Retrospective Cost Analysis of a Phase II Randomised Clinical Trial Edmonds M, Gough A, Solovera J, Standaert B *Clinical Drug Investigation* 03/1999; 17(4):275-286.
38. PSA: wat betekent een getal? Wauters A, Neels H, Libeer JC, Hamers N, Demedts P, Standaert B, Denis L *Tijdschrift Voor Geneeskunde*. 01/1998; 54(6):403-407.
39. Prostate volume and cancer in screening programs. B Standaert, A Alwan, V Nelen, L Denis *The Prostate* 12/1997; 33(3):188-94.
40. The European Randomized Study of Screening for Prostate Cancer: an update. B Standaert, L Denis *Cancer* 12/1997; 80(9):1830-4.
41. Total healthcare budget: assigning priority and level of asset allocation to the diagnosis and management of urologic diseases. B Standaert. *Urology* 10/1995; 46(3 Suppl A):4-11.
42. Overall and meal-specific macronutrient intake in Belgian primary school children. De Henauw S, Wilms L, Mertens J, Standaert B, De Backer G. *Ann Nutr Metab*. 1997;41(2):89-97.
43. European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies. F H Schröder, L J Denis, W Kirkels, H J de Koning, B Standaert
44. European School of Oncology Advisory report to the European Commission for the "Europe Against Cancer Programme" European Code Against Cancer P. Boyle, U. Veronesi, M. Tubiana, F.E. Alexander, F. Calais da Silva, L.J. Denis, J.M. Freire, M. Hakama, A. Hirsch, R. Kroes, [.....], J.J. Pindborg, R. Saracci, C. Scully, B. Standaert, H. Storm, S. Blanco, R. Malbois, N. Bleehen, M. Dicato, S. Plesnicar *European Journal of Cancer* 02/1995;
45. Economics of BPH: measuring the intangible costs. B Standaert, K Torfs. *Progress in clinical and biological research* 02/1994; 386:409-18.
46. Geographic and temporal stability of HIV seroprevalence among pregnant women in Bujumbura, Burundi. D C Sokal, T Buzingo, N Nitunga, P Kadende, B Standaert *AIDS* 11/1993; 7(11):1481-4.
47. Screening for prostatic hyperplasia. B Standaert, V Nelen, K Torts, L Denis, E De Smedt *The Lancet* 12/1991; 338(8775):1155.
48. The association of tuberculosis and HIV infection in Burundi. B Standaert, F Niragira, P Kadende, P Piot *AIDS Research and Human Retroviruses* 05/1989; 5(2):247-51.
49. [Evaluation of the basic health care pilot project of the Turnhout area]. C Truyen, V Nelen, J Mertens, H De Vriendt, B Standaert *Archives belges = Belgisch archief*. 02/1989; 47(1-4):11-5.
50. Acquired immunodeficiency syndrome and human immunodeficiency virus infection in Bujumbura, Burundi. B Standaert, P Kocheleff, P Kadende, N Nitunga, T Guerna, R Laroche, P Piot *Transactions of the Royal Society of Tropical Medicine and Hygiene* 02/1988; 82(6):902-4.

51. [AIDS and human immunodeficiency virus infection in Africa]. P Piot, R Colebunders, M Laga, B Standaert, H Taelman, G Van der Groen *Verhandelingen - Koninklijke Academie voor Geneeskunde van België* 02/1988; 50(6):519-60.
52. [Tropical AIDS and tuberculosis. Apropos of a survey carried out in Bujumbura within the direct setting of HIV-seropositive and -seronegative tuberculous patients]. P Kadende, B Standaert, F Niragira, G Kamamfu, R Laroche *Médecine tropicale: revue du Corps de santé colonial* 01/1988; 48(1):19-20.
53. The use of transrectal echography for screening on prostate cancer. Results and evaluation. B Standaert, J C Van der Auwera, M Chaban, A Cornet, W Eylenbosch, L Denis. *Progress in clinical and biological research* 02/1987; 243B:29-36.
54. [Malnutrition and HIV infection in children in a hospital milieu in Burundi]. Excler JL, Standaert B, Ngendandumwe E, Piot P. *Pediatric*. 1987;42(9):715-8. French.
55. [Cancer registration in Belgium]. Standaert B, Eylenbosch WJ. *Arch Belg*. 1986; 44(3-4):155-74.
56. [Health education in the early detection of prostatic diseases]. Standaert B, Eylenbosch WJ. *Arch Belg*. 1986; 44(1-2):68-75.

RESEARCH INSTITUTE SHARE

This thesis is published within the **Research Institute SHARE** (Science in Healthy Ageing and healthcaRE) of the University Medical Center Groningen / University of Groningen.

Further information regarding the institute and its research can be obtained from our internet site: <http://www.share.umcg.nl/>.

More recent theses can be found in the list below.

((co-) supervisors are between brackets)

2015

Mutsaerts M

Lifestyle and reproduction

(prof JA Land, prof BW Mol, dr A Hoek, dr H Groen)

Sulkers E

Psychological adaptation to childhood cancer

(prof R Sanderman, prof PF Roodbol, prof ESJM de Bont, dr J Fleer, dr WJE Tissing)

Febrianna SA

Skin problems related to Indonesian leather & shoe production and the use of footwear in Indonesia

(prof PJ Coenraads, prof H Soebono, dr MLA Schuttelaar)

2014

Schneeberger C

Asymptomatic bacteriuria and urinary tract infections in women: focus on diabetes mellitus and pregnancy

(prof RP Stolk, prof JJHM Erwich, dr SE Geerlings)

Skorvanek, M

Fatigue, apathy and quality of life in patients with Parkinson's disease

(prof JW Groothoff, prof Z Gdovinova, dr JP van Dijk, dr J Rosenberger)

Kolvek G

Etiology and prognosis of chronic kidney disease in children: Roma ethnicity and other risk factors

(prof SAReijneveld, prof L Podracka, dr JP van Dijk, dr J Rosenberger)

Mikula P

Health related quality of life in people with multiple sclerosis; the role of coping, social participation and self-esteem

(prof JW Groothoff, prof Z Gdovinova, dr JP van Dijk, dr I Nagyova)

Amalia R

Improving a school-based dental programme through a sociodental risk group approach

(prof RMH Schaub, prof JW Groothoff, prof N Widyanti)

Christoffers WA

Hand eczema; interventions and contact allergies

(prof PJ Coenraads, dr MLA Schuttelaar)

Troquete NAC

START-ing risk assessment and shared care planning in out-patient forensic psychiatry; results from a cluster randomized controlled trial

(prof D Wiersma, prof RA Schoevers, dr RHS van den Brink)

Golea E

Functioning of young individuals with upper limb reduction deficiencies

(prof CK van der Sluis, dr RM Bongers, dr HA Reinders-Messelink)

Nguyen HT

Medication safety in Vietnamese hospitals; a focus on medication errors and safety culture

(prof K Taxis, prof FM Haaijer-Ruskamp, prof JRBJ Brouwers, dr TD Nguyen)

Lehmann V

Singlehood and partnerships in healthy people and childhood cancer survivors; a focus on satisfaction

(prof M hagedoorn, prof R Sanderman, dr MA Tuinman)

Jaarsma EA

Sports participation and physical disabilities: taking the hurdle?!

(prof JHB Geertzen, prof PU Dijkstra, dr R Dekker)

Ockenburg SL van

Psychological states and physical fates; studying the role of psychosocial stress in the etiology of cardiovascular disease: a nomothetic versus an idiographic approach

(prof JGM Rosmalen, prof P de Jonge, prof ROB Gans)

Beijers CGHM

Unhealthy behaviors during pregnancy; who continues to smoke and consume alcohol, and is treatment of anxiety and depressive symptoms effective?

(prof J Ormel, prof CLH Bockting, dr H Burger)

Kerdijk W

Strategic choices in curriculum design to facilitate knowledge and competency development

(prof J Cohen-Schotanus, prof JW Snoek, dr R Tio)

Spaans F

Hemopexin activity and extracellular ATP in the pathogenesis of preeclampsia

(prof H van Goor, dr MM Faas, dr WW Bakker)

Brinksma A

Nutritional status in children with cancer

(prof PF Roodbol, prof R Sanderman, prof ESJM de Bont, dr WJE Tissing)

Prihodova L

Psychological and medical determinants of long-term patient outcomes; a specific focus on patients after kidney transplantation and with haemophilia

(prof JW Groothoff, dr JP van Dijk, dr I Rajnicova-Nagyova, dr J Rosenberger)

Snippe E

Understanding change in psychological treatments for depressive symptoms; the individual matters

(prof R Sanderman, prof PMG Emmelkamp, dr MJ Schroevers, dr J Fleer)

Groen B

Complications in diabetic pregnancy; role of immunology and Advanced Glycation End products

(prof TP Links, prof PP van den Berg, dr MM Faas)

Visser L

Early detection and prevention of adolescent alcohol use; parenting and psychosocial factors

(prof SA Reijneveld, dr AF de Winter)

Tovote KA

Acceptance or challenge? Psychological treatments for depressive symptoms in patients with diabetes

(prof R Sanderman, prof PMG Emmelkamp, prof TP Links)

Trippolini M

Evaluation of functioning in workers with whiplash-associated disorders and back pain

(prof MF Reneman, prof PU Dijkstra, prof JHB Geertzen)

Eriks-Hoogland IE

Shoulder impairment in persons with a spinal cord injury & associations with activities and participation

(prof LHV van der Woude, prof G Stucki, prof MWM Post, dr S de Groot)

Suwantika AA

Economic evaluations of non-traditional vaccinations in middle-income countries: Indonesia as a reference case
(*prof MJ Postma, dr K Lestari*)

Behanova M

Area- and individual-level socioeconomic differences in health and health-risk behaviours; a comparison of Slovak and Dutch cities
(*prof SA Reijneveld, dr JP van Dijk, dr I Rajnicova-Nagyova, dr Z Katreniakova*)

Dekker H

Teaching and learning professionalism in medical education
(*prof J Cohen-Schotanus, prof T van der Molen, prof JW Snoek*)

Dontje ML

Daily physical activity in patients with a chronic disease
(*prof CP van der Schans, prof RP Stolk*)

For more 2014 and earlier theses visit our website